DNA methylation analysis of progression patterns in ductal carcinoma in situ of triple-negative breast cancer

Breast cancer often begins as a quiet, contained growth called ductal carcinoma in situ, or DCIS. In this early stage, abnormal cells are trapped inside the milk ducts of the breast, unable to spread to other parts of the body. For many women, this condition remains harmless forever. For others, however, these same cells eventually break through the duct wall and become invasive, spreading into surrounding tissue and potentially to distant organs. The challenge for doctors is that current tests cannot reliably predict which patients fall into which group. This uncertainty often leads to aggressive treatment for everyone, including those whose cancer might never have progressed. To solve this, scientists are looking for molecular clues hidden within the cells themselves, specifically changes in how genes are switched on or off without altering the genetic code. One such mechanism is DNA methylation, a chemical tag that acts like a dimmer switch for genes, often silencing them when it is placed in the wrong spot. Understanding when and how these switches flip during the transition from a contained growth to an invasive cancer could one day help doctors distinguish between a lesion that needs immediate surgery and one that can be watched safely.

A team of researchers at Okayama University Hospital and Tsukioki Clinic set out to find these specific molecular switches in a particularly aggressive form of breast cancer known as triple-negative breast cancer. This subtype is defined by the absence of three common receptors that usually drive cancer growth, making it harder to treat with standard hormone therapies. The researchers focused on a unique situation where a single patient's tumor contained both the contained, non-invasive cells and the invasive cells side by side. By studying these mixed tumors, they could compare the two cell types directly, removing the confusion caused by differences between individual patients. They also included samples from patients who had only the contained form of the disease to see if there was a step-by-step progression. To get a clear view, the scientists used a precise tool called laser capture microdissection, which acts like a microscopic scalpel to cut out only the specific cancer cells from the tissue sample, leaving the healthy cells behind. They then analyzed the chemical tags on the DNA of these isolated cells to see which ones had changed as the cancer became invasive.

The study involved five patients in total. Three of them had tumors containing both the contained and invasive parts, while two had only the contained form. The invasive parts in the mixed tumors were small, measuring less than one centimeter, which helped the researchers focus on the earliest stages of invasion. After carefully isolating the cells and preparing their DNA, the team used a high-tech chip to measure the methylation levels at hundreds of thousands of sites across the genome. They looked for patterns that appeared consistently when the cancer moved from the contained state to the invasive state. In the comparison between the contained and invasive parts of the mixed tumors, the researchers found hundreds of sites where the chemical tags had changed. Most of these changes involved an increase in the tags, a process known as hypermethylation, which typically turns genes off. One specific area near a gene called RASSF1 stood out, showing a significant increase in these tags in the invasive cells compared to the contained ones. However, because the study was small, the statistical evidence was not strong enough to declare this finding a definitive rule, and the researchers described it as a promising lead that needs further testing.

The researchers also looked at the broader picture by comparing the contained cells from the mixed tumors with the contained cells from the patients who had no invasive cancer at all. Here, they found a different pattern. Instead of an increase in tags, the contained cells that were sitting next to invasive cancer showed a decrease in tags compared to the contained cells that were alone. This suggests that the presence of an invasive component might be linked to a different chemical environment within the tumor, even before the invasion happens. Furthermore, the team identified hundreds of sites where the chemical tags changed in a steady, step-by-step manner across the three groups: starting with the contained-only group, moving to the contained part of the mixed group, and finally reaching the invasive part. Some of these sites showed a steady increase in tags, while others showed a steady decrease. These stepwise changes offer a potential roadmap of how the cancer evolves, suggesting that the shift toward invasion is not a sudden event but a gradual accumulation of molecular changes.

Despite these intriguing patterns, the authors are careful to emphasize that their findings are exploratory. The study included only five patients, which is a very small number for this type of genetic research. Because of this small size, the statistical confidence was not high enough to rule out the possibility that the results happened by chance. The researchers explicitly state that none of the findings should be used to make medical decisions at this time. The RASSF1 region, which showed the most dramatic change, requires confirmation in larger groups of patients. Additionally, the study did not include normal breast tissue, so it is unclear if these changes started before the cancer formed or appeared only as it became invasive. The team also noted that they did not have information on whether the patients carried inherited genetic mutations, which could influence the results.

The value of this work lies in its method and its direction rather than in a final answer. By isolating the specific cells and comparing them within the same patient, the researchers created a clearer picture of the molecular differences between contained and invasive cancer than previous studies that mixed different patients together. They have identified a list of candidate genes and regions that might act as markers for invasion in triple-negative breast cancer. These candidates, including the RASSF1 region and the hundreds of stepwise changing sites, now serve as a starting point for future research. The next steps will involve testing these leads in larger groups of patients and checking if they can predict which contained cancers will eventually become invasive. Until then, the study remains a careful, scientific exploration of the invisible chemical changes that might one day help doctors spare patients from unnecessary surgery while ensuring others get the treatment they need.